Mhairi Copland, MB ChB, PhD, University of Glasgow, Glasgow, UK, briefly discusses the current state of the art in chronic myeloid leukemia (CML), emphasizing the importance of increasing the number of patients on tyrosine kinase inhibitor (TKI) therapy who achieve treatment-free remission. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
M.C. has received research funding from Cyclacel and Incyte, is/has been an advisory board member for Novartis, Incyte, Jazz Pharmaceuticals, Pfizer and Servier, and has received honoraria from Astellas, Novartis, Incyte, Pfizer and Jazz Pharmaceuticals.